Psyched: Psychedelic Therapy In The Workplace, UCL’s Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal’s Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health
The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
Psyched: Musk’s Empathy Tweets, Psychedelics In Congress, Oregon’s Opt-Outs, MAPS’ MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics
Psyched: Brock Pierce Joins Psychedelic VC, Colorado’s Psychedelics Legalization, Zappy Zapolin’s Open Letter & More
Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'
Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant’s LSD Therapy & More
15 Global Psychedelics Executives To Keep An Eye On In 2022
Psyched: VC Fund Invests $50M In Psychedelics, Musk’s ‘Exploratory Journeys’, Native American Use Of Peyote And More
Palo Santo Closes $50M Investment Fund
Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund.
AdvisorShares Expands Cannabis ETF Offerings, Launches MSOS 2X Daily ETF MSOX
AdvisorShares revealed that the AdvisorShares MSOS 2x Daily ETF (ARCA:MSOX) will begin trading on August 24th.
Are Psychedelics Stocks In Trouble Or Is The Market Reaching Maturity?
Long gone is the heyday of investor enthusiasm and easy access to capital that marked the launch of the psychedelics industry into the public markets.
In recent months, psychedelics stocks entered into a period of turmoil characterized by declining valuations and a generalized capital dry spell.